- Home
- SHG vs RPRX Comparison
SHG vs RPRX Comparison
Compare SHG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHG
- RPRX
- Stock Information
- Founded
- SHG 1982
- RPRX 1996
- Country
- SHG South Korea
- RPRX United States
- Employees
- SHG N/A
- RPRX N/A
- Industry
- SHG Major Banks
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- SHG Finance
- RPRX Health Care
- Exchange
- SHG Nasdaq
- RPRX Nasdaq
- Market Cap
- SHG N/A
- RPRX 14.2B
- IPO Year
- SHG N/A
- RPRX 2020
- Fundamental
- Price
- SHG $31.76
- RPRX $31.37
- Analyst Decision
- SHG
- RPRX Strong Buy
- Analyst Count
- SHG 0
- RPRX 5
- Target Price
- SHG N/A
- RPRX $41.60
- AVG Volume (30 Days)
- SHG 273.4K
- RPRX 4.2M
- Earning Date
- SHG 04-25-2025
- RPRX 05-08-2025
- Dividend Yield
- SHG 1.83%
- RPRX 2.81%
- EPS Growth
- SHG 4.89
- RPRX N/A
- EPS
- SHG 5.71
- RPRX 1.91
- Revenue
- SHG $9,891,717,986.00
- RPRX $2,263,576,000.00
- Revenue This Year
- SHG $3.49
- RPRX $33.46
- Revenue Next Year
- SHG $2.89
- RPRX $4.44
- P/E Ratio
- SHG $5.60
- RPRX $16.41
- Revenue Growth
- SHG 2.76
- RPRX N/A
- 52 Week Low
- SHG $29.25
- RPRX $24.05
- 52 Week High
- SHG $46.05
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- SHG 46.12
- RPRX 35.44
- Support Level
- SHG $32.32
- RPRX $32.26
- Resistance Level
- SHG $33.57
- RPRX $34.14
- Average True Range (ATR)
- SHG 0.39
- RPRX 0.76
- MACD
- SHG 0.16
- RPRX -0.29
- Stochastic Oscillator
- SHG 57.94
- RPRX 11.78
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.